DNDi has various types of agreements with its partners worldwide, such as Research Services Agreements, Material Transfer Agreements, Research and License Agreements, Collaboration Agreements, Clinical Trial Agreements, Financial Agreements, etc.
Research Services Agreements regulate contractual relationship between research service providers and DNDi. Material Transfer Agreements provide access to compounds for testing. In addition to these agreements, DNDi seeks to conclude Research and License Agreements with key partners which involve a greater commitment from both parties. The core of these agreements concern IP ownership (generally owned by the partner and in some cases co-owned), and licensing clauses. Several conditions are required to ensure availability and affordability of the treatment and respect of DNDi’s IP policy objectives. As a not-for-profit and patient-needs driven organization, DNDi seeks transparency to efficiently address urgent patient needs. Therefore, the licenses should be:
- Royalty-free to ensure the lowest possible price
- Sub-licensable, or in other terms, contain the authorization to disclose the obtained information to another party in order to continue product development
- Worldwide coverage both for R&D and for manufacture
- Non-exclusive to enable third parties to enter the field (included in our most innovative agreements)
An important objective for DNDi’s agreement is limited confidentiality – to make available all information generated on the product during its development in the form of publications or databases.
Pharmaceuticals
AbbVie (USA) – Projects: Screening filarial diseases / Screening Chagas / Screening leishmaniasis / Leish Hit-to-lead / Chagas Hit-to-lead / Booster Hit-to-lead (leishmaniasis) / Booster Hit-to-lead (Chagas) / Leish L205 Series / Aminopyrazoles / Chagas C205 Series / Flubendazole Macrofilaricide / AbbV4083 / ‘4-in-1’ LPV/r/ABC/3TC
Asinex Corporation (US) – Projects: Sleeping sickness programme
Astellas Pharma Inc. (Japan) – Projects: Screening Chagas / Screening leishmaniasis
AstraZeneca (UK, Sweden) – Projects: Screening Chagas / Screening leishmaniasis / Leish Hit-to-lead / Chagas Hit-to-lead / Booster Hit-to-lead (leishmaniasis) / Booster Hit-to-lead (Chagas)
Avista Pharma (formerly SCYNEXIS Inc) (USA) – Projects: Acoziborole / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi 5610 / SCYX-2035811 / DNDi-6148
Bayer Healthcare (Germany) – Projects: Screening Chagas / Screening leishmaniasis / Emodepside
Bio-Zeq Kenya (Kenya) – Projects: Miltefosine-Paromomycin combination for Africa
Boehringer Ingelheim, Animal Health Business Unit (formerly Sanofi Merial) (USA) – Projects: Screening filarial diseases / Screening Chagas / Screening leishmaniasis
Bristol-Myers Squibb (USA) – Projects: Screening Chagas / Screening leishmaniasis
Cipla Ltd. (India) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI / ASMQ
Daiichi Sankyo (Japan) – Projects: Screening Chagas / Screening leishmaniasis / Daiichi Sankyo LH2L / Daiichi Sankyo CH2L
Daiichi Sankyo RD Novare Co., Ltd. (Japan) – Projects: Screening Chagas / Screening leishmaniasis
Debiopharm (Switzerland) – Projects: Screening
DuPont (formerly E.I du Pont Nemours) (USA) – Projects: Screening Chagas / Screening leishmaniasis
Eisai Co., Ltd. (Japan) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / Booster H2L (leishmaniasis) / Booster H2L (Chagas) / Azoles E1224 / New benz regimens +/- fosravuconazole / Fosravuconazole
Eurofins Optimed (France) – Projects: Fexinidazole-Miltefosine combination
Exeltis (USA) – Projects: Chagas disease programme
Farmanguinhos (Fiocruz) (Brazil) – Projects: ASMQ
GeneDesign Inc. (Japan) – Projects: CpG-D35
Gilead Sciences (USA) – Projects: New treatments for HIV/VL
GlaxoSmithKline (GSK) (Spain, UK) – Projects: Screening filarial diseases / Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / GSK3186899/DDD853651 & GSK3494245/DDD1305143 / New treatments for HIV/VL
Genomics Institute of the Novartis Research Foundation (GNF Novartis), Genomics Institute of the Novartis Research Foundation (USA) – Projects: Screening
Humax Pharmaceutical (Colombia) – Projects: Anfoleish
INSUD PHARMA (Argentina) – Projects: Ravidasvir/ Sofosbuvir
Johnson & Johnson (USA) – Projects: Screening filarial diseases / Screening Chagas / Screening leishmaniasis / Flubendazole Macrofilaricide
Janssen (Belgium) – Projects: Screening
Janssen Research & Development (USA) – Projects: Flubendazole Macrofilaricide
Laboratorio ELEA PHOENIX (Argentina) – Projects: New benz regimens +/- fosravuconazole / Paediatric dosage form of benznidazole / Ravidasvir/ Sofosbuvir
LAFEPE – Pharmaceutical Laboratory of Pernambuco (Brazil) – Projects: Paediatric dosage form of benznidazole / Chagas access project
Mercachem (The Netherlands) – Projects: Screening
Merck (USA) – Projects: Screening filarial disease / Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L
Merck KGaA (Germany) – Projects: Screening / Booster H2L (leishmaniasis) / Booster H2L (Chagas)
Mitsubishi Tanabe Pharma Corporation (Japan) – Projects: Screening Chagas / Screening leishmaniasis
Paladin Labs (Canada) – Projects: VL-0208
Pfizer Ltd. (formerly Anacor Pharmaceuticals) (USA) – Projects: Screening Chagas / Screening leishmaniasis / Aminopyrazoles / SCYX-1330682 SCYX-1608210 / Leish H2L / DNDi-5421 DNDi-5610 / Acoziborole / DNDi-6148 / Oxachagas
Pharco Pharmaceuticals Inc. (Egypt) – Projects: Ravidasvir/ Sofosbuvir
Pharmaniaga (Malaysia) – Projects: Ravidasvir/ Sofosbuvir
Pierre Fabre Laboratories (France) – Projects: Leishmaniasis and Chagas disease programme
Presidio Pharmaceuticals, Inc. (USA) – Projects: Ravidasvir/Sofosbuvir
Sanofi (France) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / ASAQ / Fexinidazole for T.b. gambiense / New treatments for HIV/VL
Sanofi-Chinoin (Hungary) – Projects: Fexinidazole-Miltefosine combination
Sara Pharm (Romania) – Projects: DNDi-6148
Shionogi & Co., Ldt. (Japan) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / Booster H2L (leishmaniasis) / Booster H2L (Chagas)
Syngene (India) – Projects: DNDi-6148 / DNDi-0690
Takeda Pharmaceutical Company Ltd. (Japan) – Projects: Screening Chagas / Screening leishmaniasis / Aminopyrazoles / Leish H2L / Chagas H2L / Booster H2L (leishmaniasis) / Booster H2L (Chagas) / DNDi-5561
Zenufa Laboratories Ltd (Tanzania) – Projects: ASAQ
Zoetis (formerly Pfizer Animal Health) (USA) – Projects: Screening Chagas / Screening leishmaniasis
Biotechs
Abzena (formerly Polytherics) (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.
Analyticon, Discovery Gmbh (Germany) – Projects: Sleeping sickness programme
BioAscent (UK) – Projects: Screening Chagas / Screening leishmaniasis / Leish L205 series
Celgene Corporation (USA) – Projects: Screening filarial disease / Screening Chagas / Screening leishmaniasis / CGH VL series 1 / Booster H2L (leishmaniasis) / Booster H2L (Chagas) / Macro filaricide 3
Evolva (Switzerland) – Projects: Screening
Infynity Biomarkers (France) – Projects: Chagas disease programme
iThemba Labs (South Africa) – Projects: Lead optimization
PK/Pdesign Sas (France) – Projects: CpG-D35
Sanofi Genzyme (formerly Genzyme) (USA) – Projects: Material transfer for research and development on HAT, Chagas disease, and leishmaniasis.
Sequella, Inc. (USA) – Projects: Screening Chagas / Screening leishmaniasis
Thermosurgery Technologies Inc. (USA) – Projects: New CL combination therapies
Vertex (USA) – Projects: Screening
Universities
Addis Ababa University (Ethiopia) – Projects: VL-0208 / New treatments for HIV/VL / SSG&PM
Chiang Mai University, Associated Medical Sciences/PHPT International Research Unit (Thailand) – Projects: LPV/r pellets with dual NRTI / Ravidasvir/Sofosbuvir
Banaras Hindu University, Institute of Medical Sciences (India) – Projects: New treatments for PKDL
Baylor College of Medicine Children’s Foundation (Uganda) – Projects: LPV/r pellets with dual NRTI
Centres d’Investigation Clinique des Centres Hospitaliers Universitaires de Clermont-Ferrand (France) – Projects: Fexinidazole-Miltefosine combination
Chembrige Corporation (US) – Projects: Chagas disease programme
Free University Amsterdam (The Netherlands) – Projects: Fosravuconazole
Fundacao de Apoio Universidade Federale de Sao Paolo (FapUnifesp) (Brazil) – Projects: Leish H2L / Chagas H2L
Gondar University Hospital (Ethiopia) – Projects: VL-0208 / Miltefosine-Paromomycin combination for Africa / New treatments for HIV/VL / SSG&PM
Griffith University, Griffith Institute for Drug Discovery (GRIDD) (formerly Eskitis Institute for Cell and Molecular Therapies) (Australia) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / Chagas C205 series / Leish L205 series
Imperial College London (UK) – Projects: Formulation of amphotericin B with Polytherics / Emodepside
Liverpool School of Hygiene and Tropical Medicine (LSTM) (UK) – Projects: ABBV-4083
London School of Hygiene and Tropical Medicine (UK) – Projects: Screening Chagas / Screening leishmaniasis / Aminopyrazoles / VL-0208 / VL-2098 / DNDi-5421 DNDi-5610 / CGH VL series 1 / Leish H2L / DNDi-6148 / DNDi-0690 / Fexinidazole-Miltefosine combination / New treatments for HIV/VL / SSG&PM / New VL treatments Asia / Nitroimidazole / Oxachagas / Chagas H2L / Biomarkers / Chagas C205 series / Leish L205 series
Mahidol University, Shoklo Malaria Research Unit (SMRU) (Thailand) – Projects: ASMQ / ASAQ / Emodepside
Makerere University (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa / Fexinidazole for T.b. rhodesiense
McGill University (Canada) – Projects: Biomarkers / Flubendazole Macrofilaricide
Michigan State University (USA) – Projects: Flubendazole Macrofilaricide
Moi University (Kenya) – Projects: Paediatric HIV programme
Monash University, Centre for Drug Candidate Optimization (Australia) – Projects: Fenarimol / Chagas H2L / Leish H2L / Chagas C205 series / Aminopyrazoles
Murdoch University, School of Veterinary and Biomedical Science (Australia) – Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas)
Nagasaki University (Japan) – Projects: CpG-D35
Ohio State University (USA) – Projects: CpG-D35
Osaka University (Japan) – Projects: CpG-D35
Pace University (USA) – Projects: SCYX-2035811 / SCYX-1330682 SCYX-1608210
Radboud University Medical Center (The Netherlands) – Projects: Fosravuconazole
Stellenbosch University (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
UCL School of Pharmacy (formerly London School of Pharmacy) (UK) – Projects: Formulation of amphotericin B, in collaboration with Imperial College.
Universidad Autónoma Juan Misael Saracho (Bolivia) – Projects: Biomarkers / Azoles E1224 / New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)
Universidad de San Carlos (Guatemala) – Projects: Chagas access project
Universidade de Brasilia (Brazil) – Projects: New VL treatments Latin America
Universidade Estadual de Campinas UNICAMP, Instituto de Química (Brazil) – Project: Leish H2L / Chagas H2L
Universidade Estadual de Montes Claros (Brazil) – Projects: New VL treatments Latin America
Universidade Federal do Ceará (Brazil) – Projects: Chagas access project
Universidade Federal de Goiás (Brazil) – Projects: Chagas access project
Universidade Federal de Ouro Preto (Brazil) – Projects: Fenarimol / Nitroimidazole
Universidade Federal de Piauí (Brazil) – Projects: New VL treatments Latin America
Universidade Federal de Sergipe (Brazil) – Projects: New VL treatments Latin America
Universidad Mayor de San Simon (Bolivia) – Projects: Biomarkers / Azoles E1224 / New benz regimens +/- fosravuconazole regimens / Fexinidazole (Chagas)
Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt (Peru) – Projects: New CL combination therapies
Universidad Nacional de San Martin (Argentina) – Projects: Biomarkers
Universidad São Paolo (USP) (Brazil) – Projects: Chagas H2L / Leish H2L / Chagas access project
Universidade do Estado do Rio de Janeiro (Brazil) – Projects: New VL treatments Latin America
Universidade Nova de Lisboa, Instituto de Higiene e Medicina Tropical (IHMT) (Portugal) – Projects: Fexinidazole for T.b. rhodesiense
Université de Bordeaux, Faculté de Pharmacie (France) – Projects: ASAQ
University de Antioquia, Programa de Estudio y Control de Enfermedades Tropiales (PECET) (Colombia) – Projects: Anfoleish / New CL combination therapies
University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology (Germany) – Projects: Screening filarial diseases / Macro Filaricide 3 / ABBV-4083 / Oxfendazole
University of Antwerp, Laboratory of Microbiology, Parasitology and Hygiene (Belgium) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / SCYX-1330682 SCYX-1608210 / DNDi-5421 DNDi-5610 / Aminopyrazoles / DNDi-6148 / DNDi-0690 / VL-0208 / CGH VL series 1 / Nitroimidazole / Oxachagas / Leish L205 series
University of Auckland (New Zealand) – Projects: SCYX-2035811 / Nitroimidazole / DNDi-0690
University of Buea (Cameroon) – Projects: Flubendazole Macrofilaricide
University of California (UCSF) (USA) – Projects: K777 / Superbooster therapy Paediatric HIV/TB
University of Cape Town (UCT), Division of Clinical Pharmacology Department of Medicine (South Africa) – Projects: Screening Chagas / Screening leishmaniasis / Superbooster therapy paediatric HIV/TB
University of Dundee, Drug Discovery Unit (UK) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / GSK3186899/DDD853651 & GSK3494245/DDD1305143 / DNDI-0690
University of Gedaraf (Sudan) – Projects: New treatments for PKDL
University of Glasgow (UK) – Projects: Drug discovery collaboration finding the mode of action of chemical compounds
University of Health and Allied Sciences (Ghana) – Projects: Emodepside
University of Liverpool (UK) – Projects: ABBV-4083
University of Nairobi (Kenya) – Projects: LPV/r pellets with dual NRTI
University of North Carolina, Office of Technology Development (USA) – Projects: Screening filarial diseases
University of Oxford, Infectious Diseases Data Observatory (IDDO), Worldwide Antimalarial Drug Resistance Network (UK) – Projects: ASAQ / ASMQ / Biomarkers
University of Texas at El Paso (USA) – Project: Biomarkers
University of Witswatersrand, Perinatal HIV Research Unit (South Africa) – Projects: Superbooster therapy Paediatric HIV/TB
University of Washington (USA) – Projects: Identify surrogate markers correlating with filarial worm levels to rapidly measure treatment effectiveness (filarial diseases)
University Sains Malaysia (USM) (Malaysia) – Projects: ASAQ / ASMQ
Uppsala University (Sweden) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa
Utrecht University (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection / Miltefosine-Paromomycin combination for Africa
Various academic partners (South Africa, Kenya, Uganda, Tanzania) – Projects: ‘4-in-1’ LPV/r/ABC/3TC
University “Spin-off”
Epichem (Australia) – Projects: Leish H2L / Chagas H2L / Fenarimol / Chagas C205 series / Leish L205 series
Research Institutes
Bioaster (France) – Projects: Leish L205 Series / Chagas C205 series
Broad Institute, MIT and Harvard (USA) – Projects: Screening Chagas / Screening leishmaniasis
Bureau d’Etude Ingénierie – Ste Dina Sarl (Guinea) – Projects: Fexinidazole for T.b. gambiense / Acoziborole
Commissariat à l’énergie atomique et aux énergies alternatives (France) – Projects: Project on optical imaging biomarkers to support clinical development of macrofilaricidal drugs for onchocerciasis
Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (FIPEC) (Argentina) Projects: Clinical studies for Chagas disease.
George Institute for Global Health (Australia) – Projects: ASAQ
Ifakara Health Institute (Tanzania) – Projects: ASMQ / LPV/r pellets with dual NRTI
IMEA Consulting France: Institut de Médecine et d’Epidémiologie Appliquée, Département de Santé Tropicale (France) – Projects: ASAQ
Institut Bouisson Bertrand (France) – Projects: advices for clinical trials development (filarial diseases)
Institut d’Investigacio Biomedica de Bellvitge (Spain) – Projects: Chagas disease programme
Institut National de Recherche Biomédicale (DRC) – Projects: Acoziborole / Fexinidazole for T.b. gambiense
Institut Pasteur (France) – Projects: Screening
Institut Pasteur Korea (South Korea) – Projects: Screening Chagas / Screening leishmaniasis/ Leish H2L / Chagas H2L / Fenarimol
Institut de Recherche pour le Développement (IRD) (France) – Projects: Acoziborole / Fexinidazole for T.b. gambiense / Fexinidazole for T.b. rhodesiense / Identify surrogate markers correlating with filarial worm levels to rapidly measure treatment effectiveness: Imaging technique Diffuse Reflectance Spectroscopy (DRSsr) & advice for clinical trials development (filarial diseases)
Institut de Recherche pour le Développement (IRD) (Sénégal) – Projects: ASAQ
Institute of Tropical Medicine Antwerp (Belgium) – Projects: Acoziborole/ Fexinidazole for T.b. gambiense / New treatments for HIV/VL / VL-0208 / New VL treatments Asia / ‘4-in-1’ LPV/r/ABC/3TC
Institute of Endemic Disease (IEND), Khartoum University (Sudan), Leishmaniasis East Africa Platform (LEAP) – Projects: VL-0208 / SSG&PM / Fexinidazole-Miltefosine combination / New treatments for PKDL / Fosravuconazole / Miltefosine-Paromomycin combination for Africa
Instituto Nacional de Epidemiología Dr Fatala Cháben (Argentina) – Projects: Biomarkers / New benz regimens +/- fosravuconazole / Paediatric dosage form of benznidazole
Instituto de Ciencias Biomedicas Universidade de Sao Paulo (Brazil) – Projects: Drug discovery for leishmaniasis
Instituto de Salud Carlos III (Spain) – Projects: New treatments for PKDL
International Development Research Centre (IDRC) (Canada and Uruguay) – Projects: Chagas access project
Kenya Medical Research Institute (Kenya) – Projects: Fexinidazole-Miltefosine combination / Miltefosine-Paromomycin combination for Africa / LPV/r pellets with dual NRTI / SSG&PM / ASAQ / ASMQ
KIT (Kononklijk Instituut voor de Tropen) Royal Tropical Institute (The Netherlands) – Projects: VL-0208 / Fexinidazole-Miltefosine combination
Kitasato Institute for Life Sciences (Japan) – Projects: Screening Chagas / Screening leishmaniasis
Laboratoire La Reference (Guinea) – Projects: Acoziborole
Leti, CEA (France) – Projects: Biomarkers / Identify surrogate markers correlating with filarial worm levels to rapidly measure treatment effectiveness: Imaging technique Diffuse Reflectance Spectroscopy (DRSsr) (filarial diseases)
Luxembourg Institute of Health (Luxembourg) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas) / Acoziborole
Medical Research Council (MRC) (UK) – Projects: ‘4-in-1’ LPV/r/ABC/3TC
Necker Institute (France) – Projects: ‘4-in-1’ LPV/r/ABC/3TC
Northwick Park Institute for Medical Research (UK) – Projects: Screening filarial diseases / Screening Chagas / Screening leishmaniasis / Macro Filaricide 3 / Oxfendazole
Nyumbani Lea Toto Project, Children of God Relief Institute (COGRI) (Kenya): LPV/r pellets with dual NRTI
Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) (India) – Projects: New treatments for PKDL / New VL treatments Asia / New treatments for HIV/VL
Research Foundation for Tropical Diseases and the Environment (REFOTDE) (Cameroon) – Projects: Identify surrogate markers correlating with filarial worm levels to rapidly measure treatment effectiveness: Imaging technique Diffuse Reflectance Spectroscopy (DRSsr) (filarial diseases)
Shandukani Research Centre Wits Reproductive Health and HIV Institute (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
The Netherlands Cancer Institute (The Netherlands) – Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL / VL-0208 / New treatments for PKDL / Miltefosine-Paromomycin combination for Africa
The Swiss Tropical and Public Health Institute (Switzerland) – Projects: Screening Chagas / Screening leishmaniasis / Leish H2L / Chagas H2L / Acoziborole / Fexinidazole for T.b. gambiense / Fexinidazole for T.b. rhodesiense / NECT / SSG&PM / LPV/r pellets with dual NRTI
University of Georgia Research Foundation (USA) – Projects: Biomarkers
University of Georgia, The Center for Tropical and Emerging Global Diseases (CTEGD) (USA) – Projects: Azoles E1224
Walter Reed Army Institute (USA) – Projects: Screening
Washington University in St. Louis (USA) – Projects: Chagas disease programme
National Research Centres
Administración Nacional de Laboratorios e Institutos de Salud (ANLIS), Centro Nacional de Diagnóstico e Investigación de Endemo-epidemias (Argentina) – Projects: Paediatric dosage form of benznidazole
B.P Koirala Institute of Health Sciences (Nepal) – Projects: Clinical trials for visceral leishmaniasis.
Brazilian Biosciences National Laboratory (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM) (Brazil) – Projects: Screening Chagas / Screening leishmaniasis / Chagas H2L
Center of Excellence for Chagas Disease (CECD) (USA) – Projects: Chagas access project
Centre National de Recherche et de Formation sur le Paludisme (CNRFP) (Burkina Faso) – Projects: ASMQ
CSIR – Central Drug Reseach Institute (India) – Projects: VL-2098 / DNDi-0690
Erasmus Medical Centre (The Netherlands) – Projects: Fosravuconazole / epidemiological studies on filarial diseases
Fiocruz, Fundaçao Oswaldo Cruz (Brazil) – Projects: Azoles E1224 / Chagas access project
Indian Council of Medical Research (ICMR) (India) – Projects: New VL treatments Asia / ASAQ / ASMQ
Instituto Rene Rachou, Fiocruz Minas (Brazil) – Projects: New VL treatments Asia / New VL treatments Latin America
International Centre for Diarrhoeal Disease Research (icddr,b) (Bangladesh) – Projects: New treatments for PKDL / New VL treatments Asia
IS Global, Centre de Recerca en Salut Internacional de Barcelona (CRESIB) (Spain) – Projects: Screening Chagas / Biomarkers / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas) / Azoles E1224
Joint Clinical Research Centres (Uganda) – Projects: LPV/r pellets with dual NRTI
Kala Azar Medical Research Centre (India) – Projects: New treatments for PKDL / New VL treatments Asia
Mycetoma Research Centre, Soba University Hospital (Sudan) – Projects: Fosravuconazole
National Institute for Medical Research (NIMR) (Tanzania) – Projects: ASMQ
National Institute of Health (Colombia) – Projects: Chagas access project
National Institutes of Health (USA) – Projects: Screening filarial diseases / CpG-D35
National Institute of Pathology (India) – Projects: New treatments for PKDL
National Vector Borne Disease Control Programme (India) – Projects: New VL treatments Asia
Novartis Centre de la Recherche Santé Animale (Switzerland) – Projects: Screening filarial diseases
Seattle Institute for Biomedical and Clinical Research (SIBCR) (USA) – Projects: Discovery for NTDs.
Texas Biomedical Research Institute (USA) – Projects: Biomarkers
Uganda National Health Research Organisation (UNHRO) (Uganda) – Projects: Fexinidazole for T.b. rhodesiense
NGOs/IOs
AEDES, the European Agency for Development and Health, consulting company for social and public health sector (Belgium) – Projects: ASAQ
AWOL (UK) – Projects: ABBV-4083
Clinton Health Access Initiative (USA) – Projects: LPV/r pellets with dual NRTI / ‘4-in-1’ LPV/r/ABC/3TC
Collective of Applied Studies and Social Development (CEADES) (Bolivia) – Projects: Azoles E1224 / New benz regimens +/- fosravuconazole / Fexinidazole (Chagas) / Access projects for Chagas disease
Communauté Baptiste du Congo (CBCO) (Democratic Republic of Congo) – Projects: Fexinidazole for T.b. gambiense
Enhancing Care Foundation (ECF) (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
Epicentre (France) – Projects: NECT / ASAQ / ASMQ / Fexinidazole for T.b. rhodesiense
Epicentre Research Center (Uganda) – Projects: LPV/r pellets with dual NRTI
Family AIDS Care and Education Services (FACES) Project (Kenya) – Projects: LPV/r pellets with dual NRTI
Fundación Mundo Sano (Argentina) – Projects: New benz regimens +/- fosravuconazole / Paediatric dosage form of benznidazole / Ravidasvir/Sofosbuvir / Chagas access project
HIV i-Base (UK) – Projects: Paediatric HIV programme
IDA Foundation (The Netherlands) – Projects: VL-0208 / SSG&PM
i+solutions (The Netherlands) – Projects: VL-0208 / SSG&PM / New treatments for PKDL
Institute of Microbial Chemistry(Japan) – Projects: Screening Chagas / Screening leishmaniasis
The International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS) (Brazil and Colombia) – Projects: Chagas access project
Management and Development for Health (MDH) (Tanzania) – Projects: LPV/r pellets with dual NRTI
Médecins Sans Frontières – Projects: ASAQ / NECT / Fexinidazole for T.b. gambiense / Fexinidazole-Miltefosine combination / New treatments for HIV/VL / VL-0208 / New VL treatments Asia / SSG&PM / Generic Ambisome / Biomarkers / Azoles E1224 / Fexinidazole (Chagas) / Chagas access project / ‘4-in-1’ LPV/r/ABC/3TC / Ravidasvir/Sofosbuvir
Offre Technique d’Etude et de Coopération Internationale (OTECI) (France) – Projects: ASMQ
Royal Society of Chemistry (UK): MoU to promote open source discovery.
Salvensis (UK) – Projects: Screening filarial diseases
UNITAID (Switzerland) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI
WHO-NTD (Neglected Tropical Diseases department) (Switzerland) – Projects: Fexinidazole (HAT)
WHO-TDR, Special Programme for Research and Training in Tropical Diseases (Switzerland) – Projects: ASAQ / ASMQ / Screening Chagas / Screening leishmaniasis / New VL treatments Asia
PDPs/PPPs
FIND, Foundation for Innovative New Diagnostics (Switzerland) – Projects: Collaboration and material transfer agreement to develop an ELISA-based diagnostic test for leishmaniasis. MoU for collaboration in the field of neglected tropical diseases.
Lygature (formerly TI Pharma) (The Netherlands) – Projects: DNDi partner for discovery activities.
Medicines for Malaria Venture (MMV) (Switzerland) – Projects: Screening filarial diseases / ASAQ / ASMQ
Novartis Institute for Tropical Diseases (Singapore) – Projects: Lead optimization
Institute for One World Health (OWH) (USA) – Projects: VL-0208 / New VL treatments Asia / SSG&PM
TB Alliance (USA) – Projects: Nitroimidazole / SCYX-2035811 / VL-2098 / Screening Chagas / Screening leishmaniasis / DNDi-0690
Hospitals
Academic Medical Center in Amsterdam (The Netherlands) – Projects: Miltefosine-Paromomycin combination for Africa
Amudat General Hospital (Uganda) – Projects: Fexinidazole-Miltefosine combination / SSG&PM / Miltefosine-Paromomycin combination for Africa
Arba Minch Hospital (Ethiopia) – Projects: SSG&PM
Casa de Chagas, Pernambuco (Brazil) – Projects: Chagas access project
CHUV, Centre Hospitalier Universitaire Vaudois (Switzerland) – Projects: ASMQ
Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
E.S.E Hospital San Pedro Claver Mogotes (Colombia) – Projects: Chagas access project
E.S.E. San Antonio de Soatá Hospital (Colombia) – Projects: Chagas access project
E.S.E. San Antonio de Tame (Colombia) – Projects: Chagas access project
Fundacio Investigacio Hospital General Valencia (Spain) – Projects: Chagas disease programme
Gertrude’s Children’s Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI
Hospital Clinic de Barcelona (Spain) – Projects: Fexinidazole (Chagas)
Hospital de Niños de Jujuy (Argentina) – Projects: Paediatric dosage form of benznidazole
Hospital de Niños Dr. Ricardo Gutiérrez (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole / Biomarkers
Hospital de Sant Joan Despí Moisès Broggi and Hosptial General de l’Hospitalet, Consorci Sanitari Integral (Spain) – Projects: Fexinidazole (Chagas)
Hospital General Universitari de Valencia, Fundacio Investigacio (Spain) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas)
Hospital Independencia, Centro de Chagas y Patologia Regional (Argentina) – Projects: Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole
Hospital Kuala Lumpur (Malaysia) – Projects: Ravidasvir/Sofosbuvir
Hospital Público Materno Infantil (Argentina) – Projects: Paediatric dosage form of benznidazole
Hospital Regional de la Orinoquía ESE (Colombia) – Projects: Chagas access project
Hospital Sao José de Doencas Infecciosas (Brazil) – Projects: New VL treatments Latin America
Hosptial Universitario La Paz (Spain) – Projects: Chagas disease programme
Kacheliba District Hospital (Kenya) – Projects: Fexinidazole-Miltefosine combination / Miltefosine-Paromomycin combination for Africa
KATH, Komfo Anokye Teaching Hospital (Ghana) – Projects: ASAQ
Kenyatta National Hospital (KNH) (Kenya) – Projects: LPV/r pellets with dual NRTI
Kimalel Hospital (Kenya) – Projects: Leishmaniasis programme
Mbagathi District Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI
Moi Teaching and Referral Hospital (Kenya) – Projects: LPV/r pellets with dual NRTI
Muzaffarpur Hospital (India) – Projects: New treatments for PKDL
National Museum of Natural History Paris (MNHN) (France) – Projects: Screening filarial diseases / Macro Filaricide 3 / Oxfendazole
Paediatric Hospital Joao Paulo II – FHEMIG (Brazil) – Projects: New VL treatments Latin America
Shaheed Suhrawardy Medical College and Hospital (Bangladesh) – Projects: New VL treatments Asia
SK Hospital Mymensingh (Bangladesh) – Projects: New treatments for PKDL
St. Lumumba Health Centre (Kenya) – Projects: LPV/r pellets with dual NRTI
Tygerberg Children’s Hospital (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
Vall d’Hebron University Hospital (Spain) – Projects: Fexinidazole (Chagas)
University Hospitals of Geneva (HUG) (Switzerland) – Projects: Biomarkers / Macro Filaricide 3 / Ravidasvir/Sofosbuvir
Ministries of Health/Governmental Organizations
Gedarif MoH (Sudan). Leishmaniasis East Africa Platform (LEAP) – Projects: Various partnerships for clinical trials in the field of leishmaniasis / VL-0208 / SSG&PM
Goiás State Department of Health (Brazil) – Projects: Chagas access project
Bihar State Health Society (India) – Projects: New VL treatments Asia
Centre for Disease Control and Prevention CDC/President’s Emergency Plan for AIDS Relief (USA) – Projects: ‘4-in-1’ LPV/r/ABC/3TC
Centro Nacional de Diagnostico e Investigacion de Endemo-epidemias (CeNDIE), Ministry of Health (Argentina) – Projects: Paediatric dosage form of benznidazole
Clinical Research Malaysia, Ministry of Health (Malaysia) – Projects: Ravidasvir/Sofosbuvir
Department of Health and Department of Science and Technology (South Africa) – Projects: Superbooster therapy paediatric HIV/TB
Department of Health South Africa (South Africa) – Projects: ‘4-in-1’ LPV/r/ABC/3TC / LPV/r pellets with dual NRTI
Food & Drug Administration (FDA) (US) – Projects: CpG-D35
Health Secretary of Boyacá, Casanare, Mogotes, Santader, and Soatá (Colombia) – Projects: Chagas access project
Ministry of Health (Brazil) – Projects: New VL treatments (Latin America) / Chagas access project
Ministry of Health, National Malaria Control Programme (Burundi) – Projects: ASAQ
Ministry of Health (Cambodia) – Projects: ASMQ
Ministry of Health and Social Protection (Colombia) – Projects: Chagas access project
Ministry of Health (DRC) – Projects: Various partnerships (financial and clinical trial agreement) in the field of HAT / NECT
Ministry of Health, Neglected Tropical Disease Directorate (Ethiopia) – Projects: SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa
Ministry of Health (Ghana) – Projects: ASAQ
Ministry of Health (Kenya) – Projects: LPV/r pellets with dual NRTI / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa
Ministry of Health (Sierra Leone) – Projects: ASAQ
Ministry of Health, the Neglected Tropical Diseases Unit, Leishmaniasis Programme (Sudan) – Projects: New treatments for PKDL / SSG&PM / VL-0208 / Miltefosine-Paromomycin combination for Africa
Ministry of Health (Tanzania) – Projects: Paediatric HIV programme
Ministry of Health, Leishmaniasis Control Programme (Uganda) – Projects: SSG&PM / VL-0208
Ministry of Health and Child Care (Zimbabwe) – Projects: Paediatric HIV programme
Ministry of Health and Family Welfare (Bangladesh) – Projects: New VL treatments Asia
Ministry of Health and Ministry of Industry, Science and Technology (Thailand) – Projects: Ravidasvir/Sofosbuvir
Ministry of Health and Population (Malawi) – Projects: Fexinidazole for T.b. rhodesiense
Ministry of Health and Social Assistance (Guatemala) – Projects: Chagas access project
Ministry of Health, Province of Jujuy (Argentina) – Projects: Paediatric dosage form of benznidazole
National Control Programmes (DRC, Central African Republic, Guinea) – Projects: Fexinidazole for T.b. gambiense
National Trypanosomiasis Control Programme (DRC) – Projects: NECT / Acoziborole
Programa Nacional de Leishmaniasis (Colombia) – Projects: New CL combination therapies
Soatá Town Hall, Boyacá (Colombia) – Projects: Chagas access project
Special Administrative Health Unit – Arauca Department (Colombia) – Projects: Chagas access project
Contract Research Organizations (CROs)
Accelera (Italy) – Projects: VL-2098 / DNDi-0690 / DNDi-6148 / Fexinidazole for T.b. gambiense
Aesica (UK) – Projects: Acoziborole
Amatsi Aquitaine (formerly Bertin Pharma) (France) – Projects: ASAQ / VL-2098 / Fexinidazole for T.b. gambiense / Acoziborole / CpG-D35
Analytical Services International (UK) – Projects: Emodepside
Aptuit (Italy) – Projects: DNDi-0690 / Fexinidazole-Miltefosine combination for Africa / VL-2098 / Fexinidazole for T.b. gambiense
BaseCon (Denmark) – Projects: Fexinidazole-Miltefosine combination for Africa / New treatments for HIV/VL / Fexinidazole for T.b. gambiense
Bioclinica (formerly CoreLab Partners) (France) – Projects: Azoles E1224
Biotrial (France) – Projects: Fexinidazole for T.b. gambiense
Cardiabase (Banook Group) (France) – Projects: Fexinidazole-Miltefosine combination for Africa / Fexinidazole for T.b. gambiense / Acoziborole
Calvert Labs (USA) – Projects: Pre-clinical phase for topical formulation against cutaneous leishmaniasis.
Cardinal Health (formerly Cardinal System) (France) – Projects: Azoles E1224
Catalent (USA) – Projects: Screening, discovery, clinical activities as well as registration and regulatory issues in the field of malaria.
Centipharm (Axynthis Group) (France) – Projects: CMC/manufacture of fexinidazole for sleeping sickness / Fexinidazole for T.b. gambiense
Central Diagnostics (India) – Projects: Partner in the field of visceral leishmaniasis.
Certara (formerly Quantitative Solutions) (USA) – Projects: Azoles E1224
Charles River (formerly WIL Research) (France) – Projects: DNDi-6148 / Aminopyrazoles
Clinwin Research Services (Kenya) – Projects: ASMQ
Covance (UK) – Projects: VL-2098
Creapharm (France) – Projects: Fexinidazole (Chagas)
Crystallise! (Switzerland) – Projects: DNDi-6148
Doppel Pharma (Italy) – Projects: Ravidasvir/Sofosbuvir
Drugabilis (France) – Projects: Fexinidazole for T.b. gambiense / Acoziborole / Flubendazole Macrofilaricide / VL-2098
Endolytics (USA) – Projects: VL-2098
Envigo (formerly Harlan Laboratories and Huntingdon Life Sciences Limited) (Switzerland) – Projects: Pre-clinical research agreement for Chagas disease / VL-2098
Eurofins Advinus (formerly Advinus Therapeutics Ltd.) (India) – Projects: Acoziborole / VL-2098 / DNDi-0690
Eurofins CEREP (France) – Projects: Aminopyrazoles / Chagas C205 series / Leish L205 series
Eurofins Optimed (France) – Projects: Acoziborole / ‘4-in-1’ LPV/r/ABC/3TC / Fexinidazole for T.b. gambiense / DNDi-6148
Eurofins Pharma Discovery Services (formerly Eurofins Panlabs) (USA) – Projects: Aminopyrazoles / Leish L205 series
FP Clinical Pharma (Argentina) – Projects: New benz regimens +/- fosravuconazole
Frontage (USA) – Projects: Azoles E1224
GVK BIO (India) – Projects: Clinical phase for malaria and VL / New VL treatments Asia
Hammersmith Medicines Research (UK) – Projects: Emodepside
Hypha Discovery (UK) – Projects: DNDi-0690
Iktos (France) – Projects: Discovery projects for artificial intelligence
Info Kinetics Sdn Bhd (Malaysia) – Projects: Ravidasvir/Sofosbuvir
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres”, National Council of Scientific and Technological Research (INGEBI-CONICET) (Argentina) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas) / Biomarkers / Azoles E1224 / Paediatric dosage form of benznidazole
JSS Medical Research (Canada) – Projects: Anfoleish / Fexinidazole (Chagas)
Kinapse Limited (UK) – Projects: Ravidasvir/Sofosbuvir
Lamba Therapeutics Research Ldt. (India) – Projects: New treatments for PKDL
LAT Research (Argentina) – Projects: Azoles E1224 / New benz regimens +/- fosravuconazole
Nucleo de desenvolvimento farmacêutico e cosméticos (NUDFAC) (Brazil) – Projects: Azoles E1224 / Paediatric dosage form of benznidazole / New benz regimens +/- fosravuconazole
Niche Science and Technology (UK) – Projects: Emodepside
Patheon (UK) – Projects: Formulation development and manufacturing for sleeping sickness / Acoziborole
Penn Pharmaceuticals Services (UK) – Projects: Acoziborole / DNDi-0690
Pentlands Management Systems Ltd (UK) – Projects: Leishmaniasis programme
PhinC Development (France) – Projects: Fexinidazole for T.b. gambiense / Fexinidazole-Miltefosine combination for Africa / Acoziborole / New benz regimens +/- fosravuconazole
Quotient Sciences (UK) – Projects: DNDi-0690
RCTs (France) – Projects: NECT / Fexinidazole for T.b. gambiense / Acoziborole
Roowin (France) – Projects: CMC activities for sleeping sickness.
Sandexis (UK) – Projects: Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / CGH VL series 1 / Chagas H2L / DNDi-6148 / Oxachagas
SGS (France) – Projects: Clinical study of fexinidazole for sleeping sickness, subsequently performing bioanalyses / Acoziborole / Fexinidazole for T.b. gambiense
SGS (Belgium) – Projects: Fexinidazole-Miltefosine combination for Africa / Fexinidazole for T.b. gambiense
Sigma-Aldrich (UK) – Projects: VL-2098
Syneos Health, Llc. (USA) – Projects: Chagas disease programme
TCG Lifesciences (India) – Projects: Leish H2L / Chagas H2L
Theradis Pharma (France) – Projects: Fexinidazole for T.b. gambiense / Acoziborole
Toxipharm Laboratoire (France) – Projects: Ravidasvir/Sofosbuvir
Trade Factors Overseas Ltd (Great Britain) – Projects: Sleeping sickness programme
United BioSource Corporation (UBC) (Switzerland) – Projects: New treatments for HIV/VL / Fexinidazole-Miltefosine combination for Africa
WuXi AppTech (China) – Projects: Screening / Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / Oxachagas / Nitroimidazole / SCYX-2035811 / CGH VL series 1 / Chagas H2L / DNDi-6148 / DNDi-0690 / ‘4-in-1’ LPV/r/ABC/3TC / Chagas C205 series / Leish L205 series
Platforms and Networks
AMPATH (Kenya) – Projects: Paediatric HIV programme
HAT Platform – Projects: NECT / Fexinidazole for T.b. gambiense / Acoziborole
International Community of Women Living with HIV (Kenya) – Projects: Paediatric HIV programme
Leishmaniasis East Africa Platform (LEAP) – Projects: Fexinidazole-Miltefosine combination / New treatments for PKDL / New treatments for HIV/VL / SSG&PM / Fexinidazole-Miltefosine combination for Africa / VL-0208
NEPHAK (Kenya) – Projects: Paediatric HIV programme
NHEPACHA Network – Projects: Biomarkers
Platform of Integral Care for Patients with Chagas Disease (Bolivia) – Projects: New benz regimens +/- fosravuconazole / Fexinidazole (Chagas) / Azoles E1224
Please contact us at partnership@dndi.org to propose collaborative projects.